Hannah Culpepper

Hannah Culpepper

Auto-generated profile, based on publicly available information

Hannah Culpepper

Department of Surgery, MUSC, Charleston, South Carolina, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
MOMorgan Overstreet
Morgan Overstreet
HCHannah Culpepper
Hannah Culpepper
DDDeanna DeHoff
Deanna DeHoff
Mulugeta GebregziabherMulugeta Gebregziabher
Mulugeta Gebregziabher
MSMaria Aurora Posadas Salas
Maria Aurora Posadas Salas
DTDavid Taber
David Taber
Background: The outcome disparities for African American recipients of kidney transplant is a public health issue that has plagued the field of transplant since its inception. Based on national data, African American recipients have nearly twice the risk of graft loss at 5 years after transplant, when compared with White recipients. Evidence demonstrates that medication nonadherence and high tacrolimus variability substantially impact graft outcomes and racial disparities, most notably late (>2 years) after the transplant. Nonadherence is a leading cause of graft loss. Prospective multicenter data demonstrate that one-third of all graft loss are directly attributed to nonadherence. We have spent 10 years of focused research to develop a comprehensive model explaining the predominant risk factors leading to disparities in African American kidney recipients. However, there are still gaps in patient-level data that hinder the deeper understanding of the disparities. Lack of data from the patient often lead to provider biases, which will be addressed with this intervention. Culturally competent, pharmacist-led interventions in medication therapy management will also address therapeutic inertia. Pharmacist interventions will mitigate medication access barriers as well (cost and insurance denials). Thus, this multidimensional intervention addresses patient, provider, and structural factors that drive racial disparities in African American kidney recipients. Objective: This prospective, randomized controlled trial aimed to determine the impact of multimodal health services intervention on health outcomes disparities in African American recipients of kidney transplant. The aims of this study are to improve adherence and control of late clinical issues, which are predominant factors for racial disparities in kidney recipients, through a technology-enabled, telehealth-delivered, 4-level intervention. Methods: The Multifaceted Intervention to Improve Graft Outcome Disparities in African American Kidney Transplants (MITIGAAT) study is a 24-month, 2-arm, single-center (Medical University of South Carolina), 1:1 randomized controlled trial involving 190 participants (95 in each arm), measuring the impact on adherence and control of late clinical issues for racial disparities in kidney recipients, through a technology-enabled, telehealth-delivered, 4-level intervention. The key clinical issues for this study include tacrolimus variability, blood pressure, and glucose control (in those with diabetes mellitus). We will also assess the impact of the intervention on health care use (hospitalizations and emergency department visits) and conduct a cost-benefit analysis. Finally, we will assess the impact of the intervention on acute rejection and graft survival rates as compared with a large contemporary national cohort. Results: This study was funded in July 2023. Enrolled began in April 2024 and is expected to be complete in 2026. All patients will complete the study by the end of 2028. Conclusions: In this protocol, we describe the study design, methods, aims, and outcome measures that will be used in the ongoing MITIGAAT clinical trials. Trial Registration: ClinicalTrials.gov NCT06023615; https://www.clinicaltrials.gov/study/NCT06023615 International Registered Report Identifier (IRRID): PRR1-10.2196/57784

1 January 2025 in International Journal of Hepatology
Verified
Journal Article
Open access
KCKelsey S. Coffman
Kelsey S. Coffman
GRGonzalo J. Revuelta
Gonzalo J. Revuelta
NDNathan DeTurk
Nathan DeTurk
CPCharles Palmer
Charles Palmer
HCHannah Culpepper
Hannah Culpepper
DTDavid J. Taber
David J. Taber
Background/Aims: Neurotoxicity is commonly seen in liver transplant (LT) patients receiving tacrolimus. We sought to determine the impact of LCP tacrolimus on neurologic toxicity in LT recipients. Methods: This single‐center, semiblinded, parallel group randomized controlled trial compared neurotoxicity burden in LT patients receiving immediate‐release (IR) tacrolimus versus LCP tacrolimus. Thirty LT recipients transplanted between January 2020 and February 2022 were enrolled between 15 and 364 days posttransplant and followed for 6 months postrandomization. The primary endpoint was change from baseline to 6 months in composite Patient Global Impression of Improvement (PGI‐I) score. Select secondary endpoints included change in Fahn–Tolosa–Marin (FTM) Tremor Rating Scale, IMAB‐Q10, SF‐12, and Medical Symptom Validity Test (MSVT) scores. Results: No significant differences were seen in composite PGI scores, though all patients saw improvement in overall PGI scores (IR −5 [−13.5 to −0.25] vs. LCP −4 [−9.5 to −0.5], p = 0.78). Other tests examining neurotoxicities showed no difference between groups but an overall trend toward improvement in symptoms between baseline and end of study. One episode of moderate rejection (rejection activity index [RAI] score of 6) was reported in the LCP group, with no episodes in the IR group ( p = 0.31). No graft loss or mortality occurred in either group. Conclusions: Our study showed LCP tacrolimus had similar rates of neurotoxicity in LT recipients compared to IR without increasing the risk of rejection, graft loss, or mortality; these results suggest LCP tacrolimus can be a safe alternative in LT recipients. Trial Registration: ClinicalTrials.gov identifier: NCT03823768

27 February 2024 in JMIR Preprints
Verified
Preprint
Open access
MOMorgan Overstreet
Morgan Overstreet
HCHannah Culpepper
Hannah Culpepper
DDDeanna DeHoff
Deanna DeHoff
Mulugeta GebregziabherMulugeta Gebregziabher
Mulugeta Gebregziabher
MSMaria Aurora Posadas Salas
Maria Aurora Posadas Salas
DTDavid Taber
David Taber
BACKGROUND The outcome disparities for African American recipients of kidney transplant is a public health issue that has plagued the field of transplant since its inception. Based on national data, African American recipients have nearly twice the risk of graft loss at 5 years after transplant, when compared with White recipients. Evidence demonstrates that medication nonadherence and high tacrolimus variability substantially impact graft outcomes and racial disparities, most notably late (>2 years) after the transplant. Nonadherence is a leading cause of graft loss. Prospective multicenter data demonstrate that one-third of all graft loss are directly attributed to nonadherence. We have spent 10 years of focused research to develop a comprehensive model explaining the predominant risk factors leading to disparities in African American kidney recipients. However, there are still gaps in patient-level data that hinder the deeper understanding of the disparities. Lack of data from the patient often lead to provider biases, which will be addressed with this intervention. Culturally competent, pharmacist-led interventions in medication therapy management will also address therapeutic inertia. Pharmacist interventions will mitigate medication access barriers as well (cost and insurance denials). Thus, this multidimensional intervention addresses patient, provider, and structural factors that drive racial disparities in African American kidney recipients. OBJECTIVE This prospective, randomized controlled trial aimed to determine the impact of multimodal health services intervention on health outcomes disparities in African American recipients of kidney transplant. The aims of this study are to improve adherence and control of late clinical issues, which are predominant factors for racial disparities in kidney recipients, through a technology-enabled, telehealth-delivered, 4-level intervention. METHODS The Multifaceted Intervention to Improve Graft Outcome Disparities in African American Kidney Transplants (MITIGAAT) study is a 24-month, 2-arm, single-center (Medical University of South Carolina), 1:1 randomized controlled trial involving 190 participants (95 in each arm), measuring the impact on adherence and control of late clinical issues for racial disparities in kidney recipients, through a technology-enabled, telehealth-delivered, 4-level intervention. The key clinical issues for this study include tacrolimus variability, blood pressure, and glucose control (in those with diabetes mellitus). We will also assess the impact of the intervention on health care use (hospitalizations and emergency department visits) and conduct a cost-benefit analysis. Finally, we will assess the impact of the intervention on acute rejection and graft survival rates as compared with a large contemporary national cohort. RESULTS This study was funded in July 2023. Enrolled began in April 2024 and is expected to be complete in 2026. All patients will complete the study by the end of 2028. CONCLUSIONS In this protocol, we describe the study design, methods, aims, and outcome measures that will be used in the ongoing MITIGAAT clinical trials. CLINICALTRIAL ClinicalTrials.gov NCT06023615; https://www.clinicaltrials.gov/study/NCT06023615 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/57784

4 September 2024 in Research Square
Verified
Preprint
Open access
PDF file
HCHannah Culpepper
Hannah Culpepper
MOMorgan Overstreet
Morgan Overstreet
KSKarim Soliman
Karim Soliman
MCMichael Casey
Michael Casey
TRTeresa “Tracy” Rice
Teresa “Tracy” Rice
DTDavid J. Taber
David J. Taber
Background: Cytomegalovirus (CMV) infection remains a significant problem in kidney transplantation despite advances in screening, monitoring, therapeutics, and management. Although universal prophylaxis with antiviral therapy has significantly reduced the risk of early CMV infection and disease, late-onset CMV is still common and can be difficult to clinically manage in high-risk patients. A recent systematic review showed that with antiviral prophylaxis, early CMV infection occurred in only 6% of kidney recipients and late infection occurred in more than one in six patients. 4 The two antiviral prophylaxis medications this study is comparing, valganciclovir (VGC) and maribavir, are highly effective at preventing CMV infection. In studies using valganciclovir, the reported occurrence of leukopenia is 20 - 40% and neutropenia is 10 - 30%6-12. In studies using maribavir, the reported occurrence of neutropenia was 4 - 5% versus 15 - 18% in valganciclovir patients. With appropriate dosing, maribavir appears to have similar efficacy to valganciclovir in treating current and preventing future CMV infection with a significantly reduced rate of neutropenia. Methods: Maribavir IIR is a 12-month, single-center, open-label, randomized controlled trial enrolling 70 patients (35 in each arm) examining the difference in preventing CMV infection while specifically assessing the tolerability of the two antiviral prophylactic medications. The trial is currently in the follow-up phase, with the first patient enrolled in November 2023, and enrollment concluding in June 2024. Discussion: The primary objective of this study is to assess the tolerability of maribavir versus valganciclovir (VGC) prophylaxis in adult kidney transplant recipients at high-risk of CMV infection (D+/R- or thymo use if R+). This was done by assessing the incidence of leukopenia in the two arms, the occurrence of CMV infection despite prophylaxis, the impact of these medications on healthcare utilization and costs, and any outcome differences associated with race and sex. In this preliminary report, we describe the study design, methods, aims, and outcome measures that will be utilized in the ongoing Maribavir IIR clinical trial. Trial Registration: ClinicalTrials.gov NCT06034925: https://www.clinicaltrials.gov/study/NCT06034925